Immunogen (IMGN) PT Raised to $24 at Oppenheimer Ahead of '853 Path Forward
Tweet Send to a Friend
Oppenheimer analyst Christopher Marai reiterated an Outperform rating and raised his price target on Immunogen Inc. (NASDAQ: IMGN) to $24.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
